Cargando…

Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G

Pathogenesis in aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorders (herein called NMO) involves complement-dependent cytotoxicity initiated by AQP4-IgG binding to astrocyte AQP4. We recently reported that rats lacking complement inhibitor protein CD59 were h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Xiaoming, Verkman, Alan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532786/ https://www.ncbi.nlm.nih.gov/pubmed/28750658 http://dx.doi.org/10.1186/s40478-017-0462-4

Ejemplares similares

Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G
por: Yao, Xiaoming, et al.
Publicado: (2017)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G
por: Felix, Christian M., et al.
Publicado: (2016)

The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica
por: Verkman, Alan S., et al.
Publicado: (2018)

Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
por: Duan, Tianjiao, et al.
Publicado: (2019)

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
por: Tradtrantip, Lukmanee, et al.
Publicado: (2019)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G
por: Asavapanumas, Nithi, et al.
Publicado: (2014)

Intravenous Neuromyelitis Optica Autoantibody in Mice Targets Aquaporin-4 in Peripheral Organs and Area Postrema
por: Ratelade, Julien, et al.
Publicado: (2011)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder
por: Eskandarieh, Sharareh, et al.
Publicado: (2019)

Clobetasol promotes remyelination in a mouse model of neuromyelitis optica
por: Yao, Xiaoming, et al.
Publicado: (2016)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury
por: Asavapanumas, Nithi, et al.
Publicado: (2014)

Evidence for classic complement activity in neuromyelitis optica
por: Jones, Melina V., et al.
Publicado: (2014)

Magnetic resonance imaging findings in a patient with seropositive neuromyelitis optica
por: Mpateni, Siviwe S., et al.
Publicado: (2018)

Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis
por: Sridhar, Siddharth, et al.
Publicado: (2014)

Response to ‘The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica’
por: Frigeri, Antonio, et al.
Publicado: (2018)

Double seropositive neuromyelitis optica associated with COVID-19: A case report
por: Antonescu Ghelmez, Dana, et al.
Publicado: (2022)

Mutagenesis of the Aquaporin 4 Extracellular Domains Defines Restricted Binding Patterns of Pathogenic Neuromyelitis Optica IgG
por: Owens, Gregory P., et al.
Publicado: (2015)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million
por: Daniëlle van Pelt, E, et al.
Publicado: (2016)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013)

Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica
por: Liu, Yiting, et al.
Publicado: (2016)

Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
por: Jarius, Sven, et al.
Publicado: (2012)

Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum Disorder With Long-Term Remission
por: Seok, Jin Myoung, et al.
Publicado: (2021)

Sporadic amyotrophic lateral sclerosis with seropositive neuromyelitis optica spectrum disorder: A case report
por: Kim, Jin Young, et al.
Publicado: (2021)

Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum
por: Ghosh MD, Ritwik, et al.
Publicado: (2022)

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats
por: Kitic, Maja, et al.
Publicado: (2013)

A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG
por: Wang, Xiaojuan, et al.
Publicado: (2018)

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
por: Lu, Angelo, et al.
Publicado: (2022)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

Investigating paraneoplastic aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorder through a data‐driven approach
por: Dinoto, Alessandro, et al.
Publicado: (2022)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Neuromyelitis optica and neuroregeneration
Publicado: (2012)

Immunotherapy of Neuromyelitis Optica
por: Bienia, Benjamin, et al.
Publicado: (2013)

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
por: Rensel, Mary, et al.
Publicado: (2021)

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
por: Mader, Simone, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4uc2na3gn2d0nbsk1ng1v9h4ri